Biotech's $10 billion opportunity
Share

Biotech's $10 billion opportunity

CNBC's Meg Tirrell reports experimental cholesterol medicines by Amgen and Regeneron represent a potential $10 billion opportunity pending FDA approval in the U.S.
01:17
Tue, Sep 2 20141:34 PM EDT